COPYRIGHT<sup>©</sup> INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

# ANTI-DIABETIC ACTIVITY OF *PSYCHOTRIA MALAYANA* JACK LEAF AQUEOUS EXTRACT IN INDUCED TYPE 1 DIABETIC ADULT ZEBRAFISH

BY

# KHALED BENCHOULA

A thesis submitted in fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmacology)

> Kulliyyah of Pharmacy International Islamic University Malaysia

> > JULY 2018

### ABSTRACT

Type 1 diabetes is a perpetual and profound disease impacting people at all ages. It is diagnosed with the loss of insulin production because of dynamic demolition of the  $\beta$ cells in the pancreas. One bottleneck of the drug discovery on type 1 diabetes is the expensive and long testing period of the established in vivo assays. Psychotria malayana has been reported traditionally to treat diabetes. Thus, the aim of this study were to develop a type 1 diabetic adult zebrafish model through chemical induction, and to evaluate the anti-diabetic activity of Psychotria malayana Jack leaf extract on the developed type 1 diabetic adult zebrafish. Different chemical inducers, streptozotocin and alloxan, with different doses were evaluated in elevating the blood glucose level of zebrafish. Two positive controls (glibenclamide and insulin) were tested for the confirmation of the developed model. Finally, the anti-diabetic activity of a traditional medicinal plant, P. malayana aqueous extract was evaluated using the developed model. LC-MS based fingerprinting of the zebrafish and the histological examinations were applied to confirm the ability of this plant to treat type 1 diabetes. The LC-MS data set was pre-processed and then statistically calculated using a multivariate data analysis, partial least square-discriminant analysis (PLS-DA). The result of this study indicated that a single intraperitoneal injection of alloxan with the dose of 300 mg/kg was the optimal dose to elevate the fasting blood glucose level of the zebrafish. The blood glucose level (>150 mg/dL) was significantly higher (P<0.05) than that of the healthy zebrafish (70-80 mg/dL), and can be maintained for 7 days. This model was able to test the anti-diabetic activity of *P. malayana* leaf extract. The plant extract with the dose of 1, 2, and 3 g/kg significantly reduced the blood glucose level of the diabetic zebrafish from  $(123.50\pm10.89)$  to  $(75.67\pm17.82)$ . 90.83±7.86, and 73.50±7.66, respectively) (P< 0.05). Furthermore, LC-MS based fingerprinting exhibited that all doses of the plant extract were able to shift the serum metabolite profile of the treated zebrafish toward the healthy group alongside PLS-DA component 2. While PLS-DA component 1 indicated that the plant extract with the dose of 3 g/kg was superior compared to other doses in shifting the metabolite profile toward the healthy zebrafish. Finally, the histopathological examination showed that this plant extract could not repair the enormous reduction of the Langerhans cells in the pancreas of the diabetic zebrafish. In addition, this extract did not affect the liver structure of the healthy zebrafish. Hence, the mode of action of this plant extract in lowering the blood glucose level should not be through the recovery of the pancreas, but through other mechanisms which is recommended to be examined in future research.

## خلاصة البحث

يعتبر مرض السكري من الأمراض الشائعة التي تصيب كبار وصغار السن. يشخص مرض السكري بارتفاع سكر الدم نتيجة لفقدان الخلايا البائية في البنكرياس وظيفتها فى إنتاج الانسولين. تعتبر حيوانات التجارب المخبرية من أحسن الطرق لدراسة الخصائص المرضية لكل الأمراض التي تصيب الانسان. بسبب الفوائد التي تقدمها zebrafish تم اختيارها لتكون نموذج مخبري لدراسة آثار الأدوية. توجد حتى الآن طريقتين فقط لجعل zebrafish تصاب بمرض السكري، إما بوضعها في محلول يحتوي على الغلوكوز أو alloxan أو بحقنها بSTZ . بالنسبة للطريقة الأولى تبقى كمية مسبب مرض السكري مجهولة لأنه لكل سمكة وزن معين وبالتالي يجب أن تكون كمية مسبب المرض واحدة ومدروسة جيدا. أما بالنسبة لـ STZ فهو يعتبر حساس للضوء وتعتبر نصف حياته قصيرة جدا (حوالي 20 دقيقة فقط) بالإضافة إلى كلفته المادية. وبالتالي فإن محلول STZ يحتاج الكثير من الجهد لحقنه للسمك خصوصا أنه يتم حقنه في ظروف معتمة. في هذه الدراسة تم اكتشاف أن الجرعة 300 ملغ لكل كيلوغرام من وزن السمكة من alloxan هي الجرعة المناسبة لتحدث مرض السكري في السمك، تم الأخذ بعين الاعتبار نسبة السكر في دم السمك الصائم ودرجة الضرر المحدث في الخلايا البائية في البنكرياس كمؤشرات على مرض السكري نوع 1. كما تم التوصل إلى أن حقنة واحدة من alloxan بالجرعة المذكورة سابقا تحدث مرض السكري لمدة أطول من جرعة STZ، بالإضافة إلى أنه تم اكتشاف أن نبات P. malayana له قدرة علاجية ضد مرض السكري في كل الجرعات المعطاة للسمك. غير أن تحاليل LC-MS بينت أن التوصيف الأيضى لدم السمك المعطى الجرعة 3 غ لكل كيلوغرام كان أفضل من الجرعتين السابقتين 1 غ لكل كيلوغرام من وزن السمكة و2 غ لكل كيلوغرام من وزن السمكة حيث أرجع التوصيف الأيضي أقرب إلى السمك السليم.

### **APPROVAL PAGE**

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Science (Pharmacology)

> Alfi Khatib Supervisor

> Wan Mohd.Azizi Wan.Sulaiman Co-Supervisor

> Ridhwan Abdul Wahab Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmacology)

Irna Elina Ridzwan Internal Examiner

Sabrina Sukardi External Examiner

This thesis was submitted to the Department of Basic Medical Sciences and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmacology)

> Muhamad Rusdi Ahmad Rusmili Head, Department of Basic Medical Sciences

This thesis was submitted to the Kulliyyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmacology)

Juliana. Md. Jaffri. Dean, Kulliyyah of Pharmacy

### DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Khaled Benchoula

Signature .....

Date .....

## INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

## DECLARATION OF COPYRIGHT AND AFFIRMATION OF FAIR USE OF UNPUBLISHED RESEARCH

## ANTI-DIABETIC ACTIVITY OF *PSYCHOTRIA MALAYANA* JACK LEAF AQUEOUS EXTRACT IN INDUCED TYPE 1 DIABETIC ADULT ZEBRAFISH

I declare that the copyright holder of this thesis are jointly owned by the student and IIUM.

Copyright © 2018 Khaled Benchoula and International Islamic University Malaysia. All rights reserved. No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

- 1. Any material contained in or derived from this unpublished research may only be used by others in their writing with due acknowledgement.
- 2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purpose.
- 3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Khaled Benchoula

Signature

Date

### ACKNOWLEDGEMENTS

Alhamdulillah, I am grateful to Allah for the good health and wellbeing that were necessary to complete this work.

My very special thank goes to my father Saleh and my mother Zahia Khettala. My love and gratitude for both of you for supporting me in every single step I have done in the past years in Malaysia. Thanks to my brothers and sisters. Thanks to my big family especially my aunt Zahira and her daughter Khaoula. Thank you for your support during the last period.

I wish to express my appreciation and thanks to my supervisor Assoc. Prof. Dr. Alfi Khatib for providing his time, effort and support for this project, thank you for accepting me as your student. I would like to thank Asst. Prof. Dr. Wan Mohd Azizi b. Wan Sulaiman and Assoc. Prof. Dr. Ridhwan Abdul Wahab for their support.

I would like to express my deepest appreciation to Prof. Dr. Hesham El-Seedi from Uppsala University, Sweden and his wife Dr. Shaden Khalifa from Karolinska Institutet, Sweden for their invaluable knowledge and wisdom.

This research project would not have been possible without the support of my crazy friends who was pushing me away from depressed feeling. Very special thanks goes to Dr. Nasser Sabour, Dr. Samir Hassani, Taha Sindi and Vuk Stefanovic. Very special thanks goes to my best friend Mohd Zharif Bin Ismail.

## **TABLE OF CONTENTS**

Abstract	ii
Abstract in Arabic	
Approval Page	
Declaration	
Copyright Page	
Ackowledgements	
Table of Contents	
List of Tables	
List of Figures	
List of Abbreviations	
	, X V II
CHAPTER ONE: INTRODUCTION	1
1.1 Background of the study	
1.2 Problem statement	
1.3 Research objectives	
1.4 Research hypothesis	
CHAPTER TWO: LITERATURE REVIEW	
2.1 Introduction	
2.2 Insulin production	
2.3 Insulin transduction pathway	
2.4 Diabetes: history and classification	
2.5 Pathogenesis of type 1 diabetes	
2.6 Mechanism of $\beta$ -cells death	
2.7 Diabetes treatment	
2.7.1 Oral hyperglycaemic treatments	
2.7.2 Insulin treatment	
2.8 Zebrafish as a diabetic model	
2.9 Metabolomics	
2.10 Analytical instruments in metabolomics	
2.11 Psychotria malayana jack	
2.11 1 Sychotria marayana jack	
CHAPTER THREE: METHODOLOGY	
3.1 Chemicals and reagents	
3.2 Instrumentations and equipments	
3.3 Development of induced type 1 diabetic zebrafish model	
3.3.1 Zebrafish maintenance	
3.3.2 Induction of hyperglicemia using streptozocin	
3.3.3 Induction of type 1 diabetes using alloxan	
3.3.4 Treatment of the zebrafish by glibenclamide and insulin	
3.4 Treatment of type 1 diabetic zebrafish by the plant extract	
3.5 LC-MS fingerprinting	
3.6 Histology study	
3.6.1 Tissue processing	
1 U	-

3.7 Statistical analysis	
	10
CHAPTER FOUR: RESULTS	
<ul><li>4.1 Development of induced type 1 diabetic zebrafish model</li><li>4.1.1 Induction of type 1 diabetic using streptozocin</li></ul>	
4.1.2 Induction of type 1 diabetic using siteptozocii	
4.1.2 Induction of type 1 diabetic using anoxan	
blood glucose level of diabetes zebrafish model	•
4.3 Evaluation of the anti-diabetes activity of psychotria malayana	
on the alloxan induced type 1 diabetes zebrafish	
4.4 LC-MS based fingerprinting of zebrafish serum	
4.5 Histological examination	
CHAPTER FIVE: DISCUSSION	61
5.1 Development of induced type 1 diabetes zebrafish model	61
5.2 Effect of glibenclamide and insulin on fasting blood glucose lev	vel
of diabetes zebrafish model	64
5.3 Anti-diabetic activity of psychotria malayana leaf on the alloxat	
induced type 1 diabetes zebrafish	65
5.4 Histological examination	67
5.5 Conclusion	
5 6 Limitation of the study	<b>CO</b>
5.6 Limitation of the study	
5.7 Future research recommendations	
	68
5.7 Future research recommendations	68 <b>70</b>
5.7 Future research recommendations	68 <b>70</b>
5.7 Future research recommendations	68 
5.7 Future research recommendations	68 
5.7 Future research recommendations	68 
5.7 Future research recommendations	
5.7 Future research recommendations	
5.7 Future research recommendations	68 
5.7 Future research recommendations <b>REFERENCES</b> <b>APPENDIX I:</b> LC-MS chromatogram of the Healthy Zebrafish Serue <b>APPENDIX II:</b> LC-MS chromatogram of the Alloxan induced type 1 Diabetic zebrafish serum <b>APPENDIX III:</b> LC-MS chromatogram of the Insulin Treated zebrafis Serum <b>APPENDIX IV:</b> LC-MS chromatogram of the Plant Extract treated Zebrafish Serum (the plant extract dose= 1 g/kg) <b>APPENDIX V:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 1 g/kg)	
5.7 Future research recommendations	
5.7 Future research recommendations	
5.7 Future research recommendations	
5.7 Future research recommendations <b>REFERENCES</b> <b>APPENDIX I:</b> LC-MS chromatogram of the Healthy Zebrafish Serue <b>APPENDIX II:</b> LC-MS chromatogram of the Alloxan induced type 1 Diabetic zebrafish serum <b>APPENDIX III:</b> LC-MS chromatogram of the Insulin Treated zebrafis Serum <b>APPENDIX IV:</b> LC-MS chromatogram of the Plant Extract treated Zebrafish Serum (the plant extract dose= 1 g/kg) <b>APPENDIX V:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 2 g/kg) <b>APPENDIX VI:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 3 g/kg) <b>APPENDIX VI:</b> LC-MS spectrum of the Healthy Zebrafish serum with the plant extract dose= 3 g/kg)	
5.7 Future research recommendations <b>REFERENCES</b> <b>APPENDIX I:</b> LC-MS chromatogram of the Healthy Zebrafish Serur <b>APPENDIX II:</b> LC-MS chromatogram of the Alloxan induced type 1 Diabetic zebrafish serum <b>APPENDIX III:</b> LC-MS chromatogram of the Insulin Treated zebrafis Serum <b>APPENDIX IV:</b> LC-MS chromatogram of the Plant Extract treated Zebrafish Serum (the plant extract dose= 1 g/kg) <b>APPENDIX V:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 2 g/kg) <b>APPENDIX V:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 3 g/kg) <b>APPENDIX VI:</b> LC-MS spectrum of the Healthy Zebrafish serum wi m/z values	68 70 m81 82 82 83 83 84 brafish 85 ebrafish 85 th the 
5.7 Future research recommendations	
5.7 Future research recommendations	
5.7 Future research recommendations <b>REFERENCES</b> <b>APPENDIX I:</b> LC-MS chromatogram of the Healthy Zebrafish Serue <b>APPENDIX II:</b> LC-MS chromatogram of the Alloxan induced type 1 Diabetic zebrafish serum <b>APPENDIX III:</b> LC-MS chromatogram of the Insulin Treated zebrafi Serum <b>APPENDIX IV:</b> LC-MS chromatogram of the Plant Extract treated Zebrafish Serum (the plant extract dose= 1 g/kg) <b>APPENDIX V:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 2 g/kg) <b>APPENDIX VI:</b> LC-MS chromatogram of the plant extract treated Zebrafish serum (the plant extract dose= 3 g/kg) <b>APPENDIX VI:</b> LC-MS spectrum of the Healthy Zebrafish serum wi m/z values <b>APPENDIX VII:</b> The loading column plot of the PLS-DA component indicating the m/z values and the represented sample grouping <b>APPENDIX IX:</b> (cont.)The loading column plot of the PLS-DA component	
5.7 Future research recommendations	
5.7 Future research recommendations <b>REFERENCES</b> <b>APPENDIX I:</b> LC-MS chromatogram of the Healthy Zebrafish Seru <b>APPENDIX II:</b> LC-MS chromatogram of the Alloxan induced type 1 Diabetic zebrafish serum <b>APPENDIX III:</b> LC-MS chromatogram of the Insulin Treated zebrafis Serum <b>APPENDIX IV:</b> LC-MS chromatogram of the Plant Extract treated Zebrafish Serum (the plant extract dose= 1 g/kg) <b>APPENDIX V:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 2 g/kg) <b>APPENDIX V:</b> LC-MS chromatogram of the plant extract treated Zebrafish Serum (the plant extract dose= 3 g/kg) <b>APPENDIX VI:</b> LC-MS spectrum of the Healthy Zebrafish serum wi m/z values <b>APPENDIX VIII:</b> The loading column plot of the PLS-DA component indicating the m/z values and the represented sample grouping	
5.7 Future research recommendations	

<b>APPENDIX XII: (Cont.) The loading column plot of the PLS-DA component 2</b>	
indicating the m/z values and the represented sample grouping	92
<b>APPENDIX XIII: (Cont.) The loading column plot of the PLS-DA component</b>	
2 indicating the m/z values and the represented sample grouping	93
APPENDIX XIV: IACUC-IIUM ethical approval letter	94
APPENDIX XV: Plant species identification letter	96
APPENDIX XVI: Publications	97

### LIST OF TABLES

Figure No.		Page No.
2.1	Summary of oral hyperglycemic treatments.	15
2.2	Summary of insulin treatment.	17
2.3	Reported adult zebrafish models for diabetes.	21
2.4	Phyto-constituents in <i>Psychotria</i> species and their biological activities.	27
4.1	The fasting blood glucose level of zebrafish after multiple injections of STZ following Intin et al. (2013).	43
4.2	The fasting blood glucose level of zebrafish at 24 hours after single injection of different doses of STZ.	44
4.3	The fasting blood glucose level of zebrafish at different times after STZ injection at dose 300 mg/kg.	45
4.4	The fasting blood glucose level of zebrafish after alloxan injection at dose of 100 mg/kg.	47
4.5	The fasting blood glucose level of zebrafish after alloxan injection at dose of 200 mg/kg.	47
4.6	The fasting blood glucose level of zebrafish after alloxan injection at dose of 250 mg/kg.	48
4.7	The fasting blood glucose level of zebrafish after alloxan injection at dose of 300 mg/kg.	48
4.8	The fasting blood glucose level of zebrafish at different time after alloxan injection at dose of 300 mg/kg.	49
4.9	The fasting blood glucose level of zebrafish after glibenclamide treatment comparing to diabetic and healthy group.	51
4.10	The fasting blood glucose level of zebrafish after insulin treatment (dose= 1 U/kg) comparing to diabetic and normal group.	52

4.11 The fasting blood glucose level of diabetic zebrafish after treatment using different doses of plant extract comparing to diabetes group, healthy group and insulin treated group.

## LIST OF FIGURES

Figure No.		Page No.
2.1	Insulin production pathway.	8
2.2	Insulin transduction pathway.	9
2.3	Pathogenesis of type 1 diabetes.	12
2.4	Adult zebrafish anatomy.	19
2.5	Leaf and fruits of Psychotria malayana Jack	25
2.6	Phyto-constituents in Psychotria species.	29
3.1	Flow chart of STZ injection methodology.	32
3.2	Flow chart of the alloxan injection methodology.	34
3.3	Flow chart of LC-MS sample preparation.	37
3.4	Protocol procedure hematoxyline and eosin staining	39
3.5	General flow chart of the experiment.	41
4.1	Fasting blood glucose level of healthy and STZ induced type 1 zebrafish in different timeline following the protocol of Intin et al. (2013). Different capital letter indicates significant difference ( $P$ < 0.05) among the values.	43
4.2	Fasting blood glucose level of zebrafish at 24 hours after single injection of STZ with various doses. Different capital letter indicates significant difference ( $P < 0.05$ ) among the values.	44
4.3	Figure 4.3 Fasting blood glucose level of zebrafish at different time after injection using STZ (300 mg/kg). Different capital letter indicates significant difference ( $P < 0.05$ ) among the values, n= 10.	45
4.4	Fasting blood glucose level of zebrafish after injected by 100, 200, 250 and 300 mg/kg of alloxan using 1% sucrose solution. Different capital letter indicates significant difference ( $P < 0.05$ ) among the values.	47

4.5	Fasting blood glucose level of zebrafish after injected by 300 mg/kg of alloxan for 8 days. Different capital letter indicates significant difference ( $P < 0.05$ ) among the values.	49
4.6	Fasting blood glucose level of the healthy, diabetes, and glibenclamide injected zebrafish group (glibenclamide dose = $1.5 \text{ mg/kg}$ ) at 48 hours after alloxan injection. Different capital letter indicates significant difference ( $P < 0.05$ ) among the values.	50
4.7	Fasting blood glucose level of diabetic zebrafish after treated by 1 U/kg of insulin, comparing to untreated group and healthy group. Different capital letter indicates significant difference ( $P$ < 0.05) among the values.	51
4.8	Fasting blood glucose level of diabetic zebrafish after treated by different doses of plant extract, comparing to diabetes, healthy and insulin treated group. Different capital letter indicates significant difference ( $P$ < 0.05) among the values.	53
4.9	Permutation results of PLS-DA.	54
4.10	The score scatter plot from the PLS-DA of the healthy group (H), diabetes group (D), insulin treated group (I), and groups treated group by the plant extract with the dose of 1 (1), 2 (2), and 3 mg/kg (3) at 24 hours after the treatments, and 48 hours after the alloxan injection.	55
4.11	Paraffin section of islet of zebrafish pancreas using hematoxylin and eosin. Healthy group sections (1: 40X magnification; 2: 100X magnification) showed normal histology of pancreas with high cellularity of Langerhans. Alloxan injected group sections (3: 40X magnification; 4: 100X magnification) showed a high reduction of endocrine islets cellularity as indicated by the arrows in alloxan group. E*: endocrine part, E: exocrine part. A: adipose tissue.	57
4.12	Paraffin section of islet of zebrafish pancreas using hematoxylin and eosin Treated group by insulin (1: 40X magnification; 2: X100 magnification) and the group treated by plant extract with the dose of 3 g/kg (3: 40X magnification; 4: 100X magnification), the islets showed a high reduction of endocrine islets cellularity as indicated by the arrows. E*: endocrine	

	part, E: exocrine part. A: adipose tissue.	58
4.13	Paraffin section of zebrafish liver using hematoxylin and eosin staining for the control group (1: 10X magnification, 2: 40X magnification). Section shows normal hepatocytes structure. B: bile ductules, PV: portal vein, V: hepatic artery, S: sinusoidal spaces	59
4.14	Paraffin section of zebrafish liver using hematoxylin and eosin staining for the diabetes group. (1 and 2: 40X magnification) section show normal structure of hepatocytes comparing to control. B: bile ductules, V: terminal hepatic venule.	59
4.15	Paraffin section of zebrafish liver using hematoxylin and eosin staining for the treated group by insulin. (1: 40X magnification, 2: 10X magnification) nodules of damaged hepatocytes separated by fibrous bands (arrows).	60
4.16	Paraffin section of zebrafish liver using hematoxylin and eosin staining for the treated group with plant extract. (1 and 2: 40X magnification) the hepatocytes show normal structure comparing to control. B: bile ductules, S: sinusoidal spaces, T portal tracts.	60
	ductures, 5. sinusorau spaces, 1 portar tracts.	00

## LIST OF ABBREVIATIONS

ADP	Adenosine diphosphate
AGES	Advanced Glycation End Products
AKT	Protein kinase B
APCI	Atmospheric pressure chemical ionization
APPI	Atmospheric pressure photoionization
ATP	Adenosine triphosphate
CNS	Central nervous system
DME	Diabetic macular edema
ESI	Electrospray ionization
FAB	Fast atom bombardment
GC-MS	Gaze chromatography- mass spectroscopy
GLP-1	Glucose transporter 1
HLA	Human leukocyte antigen
IFN-Y	Interferon gamma
IL-1β	Interleukin 1 beta
IRS	Insulin receptor substrate
K <sub>ATP</sub> channel	ATP-dependent potassium channel
LC-MS	Liquid chromatography-mass spectrometry
LC-QTOF MS	Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometer
MHC	Major histocompatibility complex
NAD+	Nicotinamide adenine dinucleotide
NADPH	Nicotinamide adenine dinucleotide phosphate
NF-KB	Transcription factor nuclear factor

NMR	Nuclear Magnetic Resonance
NO	Nitric oxide
NPDR	Non-proliferative diabetic retinopathy
PCA	Principal component analysis
PDK-1	PIP3-dependent protein kinase
PDR	Proliferated diabetic retinopathy
PIP2	phosphatidylinositol-4,5-Kinase
PNS	Peripheral nervous system
STZ	Streptozotocin
TCA	tricarboxylic acid cycle
TGF-α	Transforming growth factor
TNF-α	Tumour necrosis factor alpha
TOF	Time of fly detector
UPLC-MS	Ultra-performance liquid chromatography
VEGF	Vascular endothelia growth factor
IL-6	Interleukin 6
IL-1β	Interleukin 1β
АРОН	Apolipoprotein H
SREBF1	Sterol regulatory element-binding protein 1
ΡΡΑRα/γ	Peroxisome proliferator-activated receptor gamma
NR1H3	Nuclear receptor 1H3
LEP	Leptin

### **CHAPTER ONE**

### **INTRODUCTION**

#### **1.1 BACKGROUND OF THE STUDY**

Diabetes is a metabolic disease diagnosed by high blood glucose levels. The high blood glucose level causes numerous serious complications such as cardiovascular disease and retinopathy. Based on the Malaysian National Health Morbidity Survey (Letchuman et al., 2010), around 24,000 individuals diagnosed with type 1 diabetes. In addition, Diabetes Atlas estimates that this number will increase to 145 million individuals by 2025 (Jan Mohamed et al., 2015).

In order to understand the system biology and the underlying complex disorder as well as discovering novel drugs, a valid disease animal model is required. The analogy of the physiological mechanism and the heredity between certain animal and human is a brilliant idea through the use of animal model in understanding the concept of human diseases (Hau, 2008). The human body is a complex system containing different organs working in different functions. The interaction between the tested drugs and the organisms could not simply be explained through *in vitro* studies. Consequently, the use of animal model is important to understand drug interaction within different organs in the body system. The animal models allow studying the mechanism of absorption, distribution, metabolism, excretion, and toxicity (Swerdlow, Braff, & Geyer, 2000).

Zebrafish has been used effectively on drugs screening (Hill, Teraoka, Heideman, & Peterson, 2005). The advantages of utilizing zebrafish as an animal model are: lessen the maintenance cost, shorten period of testing, easy to control the

experimental conditions, and the most imperative preferred standpoint is the similar hereditary of zebrafish to human (around 70%) (Howe et al., 2013). The small size of zebrafish (3-5 cm) allowed them to be kept in small tank (Lieschke & Currie, 2007). Zebrafish as a vertebrate model shows a significant similarity to the human physiology system. The same carbohydrates regulated genes of mammalian have been detected in zebrafish. Moreover, the pancreas of zebrafish has the same functions as the mammalian counterpart for glucose homeostasis. It is producing and secreting insulin, glucagon, somatostatin and digestive enzymes such as amylase. Despites its advantages, the work with zebrafish requires handling skills in extracting the organs for histology purpose (Biemar et al., 2001).

There are certain products have shown promising results as hyperglycemia drugs through a screening using *in vivo* tests. However, some of these potential drugs lost the anti-diabetic activity when testing through the mammalian animal models due to the pharmacokinetics issue and/or toxicity. In this stage, the zebrafish model is worth to be developed as an alternative screening tool prior to testing on mammalian model (Tabassum, Tai, Jung, & Williams, 2015).

*Psychotria malayana* Jack is widespread plants in tropical and subtropical countries. It is known locally by different names such as 'altoko', 'dumamai', and 'kadpaayan'. Due to its curative activities, the species of Psychotria herb is used for treating different medical issues such as diabetes. Chemical studies of Psychotria species showed the presence of enormous alkaloid compounds in the aerial parts of the plant (Carvalho Junior et al., 2017). It has been traditionally used to treat gastrointestinal disease, stomachache and infections of the female reproductive system in certain countries such as India, Indonesia, and Brazil. Several studies on antioxidant, antinflammatory and antimicrobial properties of this plant have been

reported (Currais et al., 2014; Formagio et al., 2014; Tran et al., 2017). However, the scientific proof of this plant on diabetes treatment is still lacking.

Several groups of phytoconstituents have been identified in this plant. In general, all *Psychotria sp* species tend to have alkaloid together with other groups of compounds. It was reported containing different type of compounds such as: pentacyclic triterpenes (ursolic and oleanolic acid); steroids (24-methylene-cycloartanol, stigmasterol and  $\beta$ -sitosterol); glycosylated steroids (3-O- $\beta$ -D-glucosyl- $\beta$ -sitosterol and 3-O- $\beta$ -D-glucosyl-stigmasterol); polyunsaturated triterpene (squalene); the esters of glycerol (1-palmitoylglycerol and triacylglycerol); and indole alkaloids (N,N-dimethyltryptamine and N-methyltryptamine) (Soares et al., 2017). While an alkaloid hodgkinsine was reported to be present in *P. malayana* (Hadi, Rahmawati, Asnawati, Ersalena, & Azwari, 2014).

In this study, the antidiabetic activity of *P. malayana* leaf was evaluated on the induced type 1 diabetes zabrafish followed by the analysis of the serum utilizing LC-MS based fingerprinting. Metabolomics approach was applied in the fingerprinting by calculating the LC-MS dataset through multivariate data analysis. Metabolomics is an holistic approach emphasizing the analysis of all metabolites in a sample (Guasch-Ferré et al., 2016). Metabolites are small molecules (less than 1 kDa), defined as an intermediate metabolism product. The metabolites can be detected in the blood, serum and urine. Metabolomics have been used in an extensive variety of research fields, e.g. toxicology, pharmacology, microbial biotechnology, and plant biotechnology (C<sup>~</sup> uperlovic ´-Culf, Barnett, Culf, & Chute, 2010).

#### **1.2 PROBLEM STATEMENT**

Taking its advantages into consideration, zebrafish has been chosen to be an ideal animal model for different diseases including diabetes. Nevertheless, the condition to induce adult zebrafish to become type 1 diabetes was varied depend on unpredictable factors. Thus, the optimized condition to induce type 1 diabetes on zebrafish should be developed prior to testing the anti-diabetic activity of the potential samples.

The available approaches to treat diabetes disease include diet control, insulin injection, and intake of oral diabetic medications. However, the oral medications have been confirmed to be inadequate and cause several side effects, whilst insulin injection only solves the problem temporarily (Snyder & Berns, 2004). Moreover, hypertrophy as a result of many insulin injections on the body area is another complication of insulin therapy (Gkaliagkousi, Shah, & Ferro, 2007). This condition leads to the necessity of finding new drugs or treatment with minimum side effects.

Natural products are the most suitable sources due to less side effects compared to synthetic drugs and are considered as a potential database in drug discovery (Karimi, Majlesi, & Rafieian-Kopaei, 2015). One of the prospective medicinal plants is *P. malayana* which is used traditionally in the treatment of diabetes. However, the scientific proof of this plant for diabetes treatment is still lacking. Hence, a proper scientific experiment was designed in this study to proof its anti-diabetic activity.

#### **1.3 RESEARCH OBJECTIVES**

The objectives of this study are per the following:

1- Development of the type 1 diabetic model using adult zebrafish model by:

a) Determination of the optimum dose to increase the fasting blood glucose level using alloxan and streptozotocin.

b) Determination of glucose lowering activity using positive controls glibenclamide and insulin.

- 2- Evaluation of the anti-diabetic activity of *Psychotria malayana* leaf aqueous extract on the developed type 1 diabetic adult zebrafish by:
- a) Determination of serum metabolites profile using LC-MS fingerprinting.
- b) Determination of its effects on the liver and pancreas using histology examination.

### **1.4 RESEARCH HYPOTHESIS**

- 1- Zebrafish can be used as an alternative model for type 1 diabetes using chemical inducers.
- 2- *Psychotria malayana* leaf is effective in treating the induced type 1 diabetes zebrafish.

# CHAPTER TWO LITERATURE REVIEW

#### 2.1 INTRODUCTION

Diabetes mellitus is a group of diseases characterized by high blood glucose levels as a result of low insulin production, or a defect in insulin metabolism (American Diabetes Association, 2010). High levels of blood glucose can induce micro vascular damage and cause ischemic heart disease, stroke, and peripheral vascular disease, as well as other serious complications such as retinopathy, nephropathy, and neuropathy (Lazzarini, Gurr, Rogers, Schox, & Bergin, 2012). Type 1 diabetes is diagnosed with high fasting blood glucose or random blood sugar test and glycated hemoglobin (HbA1c) test (Atkinson, Eisenbarth, & Michels, 2014). Several pathogeneses are involved in the development of type 1 diabetes. Among them is the destruction of  $\beta$ cells in the islets of Langerhans, which are responsible for insulin production. Due to the insulin reduction, the metabolic abnormalities of carbohydrates, fats, and proteins occur in the cells pathways (Atkinson et al., 2014).

### 2.2 INSULIN PRODUCTION

Insulin is a peptide hormone that is synthesised and secreted from  $\beta$ -cells in the pancreas (Sonksen & Sonksen, 2000). The regulation of insulin gene expression is influenced by blood glucose levels; however, it can be activated by other hormones, such as the Glucagon-Like Peptide-1 (GLP-1) (Kjems, Holst, Vølund, & Madsbad, 2003). The primary form of insulin is known as preproinsulin, a 98 amino acid long peptide, which is cleaved in the rough endoplasmic reticulum to become proinsulin by